Escalation of adjuvant therapy in HR+ breast cancer

Nicolò Battisti, MD, The Royal Marsden NHS Foundation Trust, London, UK, shares his thoughts on exciting areas of breast cancer research likely to grow in the coming years. Dr Battisti highlights investigations into escalation of adjuvant systemic therapy in HR+ breast cancer as a key focus. Varying findings from recent large clinical trials of CDK4/6 inhibitors in addition to standard endocrine therapy have emphasized the need for longer-term follow-up results. Dr Battisti also talks on the use of ctDNA to predict who would benefit from treatment escalation, as well as advancing the management of triple negative breast cancer. This interview took place during the 17th St. Gallen International Breast Cancer Conference.


Leave a Reply